Mangalam Drugs & Organics Ltd
- P/E
- 20.8x
- 52-week range
- 22.8 – 68.98
- ROE
- −35%
- ROCE
- −14%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Mangalam Drugs & Organics Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)20.8 against a typical 34.3: cheaper than most peers (1st = cheapest).65th of 220
- Sales growth−0.2% against a typical +15.6% from a year earlier.150th of 197
- Share price, 3 months+6.1% against a typical −0.5%.70th of 200
Latest announcements
Exchange filings and their impact on the company.
- Mangalam Drugs disclosed Rs 15.6 cr cash-credit default to two banks, heightening liquidity and going-concern risk.
Mangalam Drugs and Organics said it has defaulted on cash-credit loans from Bank of Maharashtra and Bank of Baroda for over 30 days. Overdue amounts as on 15 October 2026 were Rs 9.51 crore and Rs 6.06 crore, totalling about Rs 15.57 crore. The company said it is arranging to pay the overdue amount. For a loss-making company with tight liquidity, the default risks tighter working-capital limits, penal interest and pressure on sales and profits.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil D (Issuer Not Cooperating) | — | 24 Nov 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 24 Nov 2025 | ▼ Downgrade9 notches | Crisil BB+(Issuer Not Cooperating) → Crisil D (Issuer Not Cooperating) | — | CRISIL | ₹ 115 Cr. | |
| 19 Nov 2025 | Rating action | Crisil BB+(Issuer Not Cooperating) | — | CRISIL | ₹ 115 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 12 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 14 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 26 Mar 2026 | Other business matters | To consider other business matters |
| 6 Feb 2026 | Other business matters | To consider other business matters |
| 15 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 20 Nov 2025 | Financial Results/Other business matters | MANGALAM : 20-Nov-2025 : The Company has informed the Exchange that a Board meeting to be held on November 13, 2025 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 20, 2025, To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82 | 97 | 102 | 77 | 80 | 89 | 73 | 57 | 50 | 58 | 67 | 57 |
| Expenses | 79 | 90 | 91 | 68 | 71 | 80 | 63 | 62 | 52 | 60 | 73 | 56 |
| Operating Profit | 2 | 7 | 12 | 8 | 9 | 9 | 10 | −5 | −3 | −2 | −5 | 1 |
| OPM % | 2.7% | 7.2% | 11.4% | 10.7% | 10.9% | 9.9% | 13.6% | −8.1% | −5.7% | −2.7% | −8% | 1.6% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 3 | 4 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 4 |
| Profit before tax | −5 | 0 | 4 | 1 | 1 | 1 | 2 | −13 | −12 | −10 | −13 | −7 |
| Tax % | −25.1% | −920% | 9.9% | −355.9% | −125.2% | 5.4% | 90.8% | 6.2% | −41.4% | 0% | 1.2% | 13.4% |
| Net Profit | −4 | 1 | 4 | 3 | 3 | 1 | 0 | −14 | −7 | −10 | −13 | −8 |
| EPS in Rs | −2.25 | 0.32 | 2.24 | 1.69 | 1.7 | 0.88 | 0.09 | −8.67 | −4.58 | −6.18 | −8.25 | −4.77 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −2%
- 5 Years
- −9%
- 3 Years
- −15%
- TTM
- −22%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −297%
- 10 Years
- −16%
- 5 Years
- −29%
- 3 Years
- −36%
- TTM
- —
- 10 Years
- 4%
- 5 Years
- −4%
- 3 Years
- −11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Mangalam Drugs & Organics Ltd | ₹ 28.80 | — | 20.8x | — | −35% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 36.6x | 5.3x | 0% | 0% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.3x | 14.8x | 0% | 0% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 75.8x | 20x | 0% | 0% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.7x | 4.2x | 0% | 0% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.6x | 3.2x | 0% | 0% |
Management
- Govardhan Murlidhar Dhoot
- Executive Chairman of the Board, Managing Director
- Jeevan Mukund Dalvi
- Chief Financial Officer
- Shweta Patel
- Compliance Officer, Company Secretary
- Brijmohan M. Dhoot
- Whole-time Director
Prices are delayed and for information only. Nothing on this page is investment advice.